[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541692":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":59,"collaborators":32,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":32,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A: 4-aminopyridine","ACTIVE_COMPARATOR","dalfampridine (generic) 10 mg capsule po every 12 hours",[13],"Drug: 4-Aminopyridine",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B: Placebo","PLACEBO_COMPARATOR","Placebo-1 capsule po every 12 hours",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","4-Aminopyridine","Active study drug",[9],[27],"4AP, dalfampridine",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo comparator",[15],null,[34],{"name":35,"affiliation":5,"role":36},"John Elfar, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Andrea Horne","CONTACT","520-626-6456","ahh@arizona.edu",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Tucson","Arizona","85724","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-110.92648,32.22174,{"lat":55,"lon":54},[58],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"SPONSOR_INVESTIGATOR","John Elfar","Tenured Professor, Chairman, Department of Orthopaedic Surgery","100541692","phase-2-4-aminopyridine-for-skin-wound-healing-100541692",false,"NCT06333171","4-aminopyridine for Skin Wound Healing","Inclusion Criteria:\n\n* Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.\n* Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.\n* Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).\n* Adults subject aged 18-70\n* Ability to give written informed consent.\n* Capable of safely coming in for follow up visits on all scheduled appointments.\n\nExclusion Criteria:\n\n* History of multiple sclerosis, stroke or any other diagnosed neurological disorder\n* History of hypersensitivity to AMPYRA® or 4-aminopyridine\n* Current use of aminopyridine medications, including other compounded 4-AP\n* Suspected renal impairment based on the Choyke questionnaire.\n* History of difficult compliance with timely follow up\n* Patients outside the age range\n* Unable to provide informed consent.\n* Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).\n* Patients with a concomitant traumatic brain injury.\n* Patients unable to communicate.\n* Patients unwilling to complete the study requirements.\n* Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.\n* Pregnancy, breastfeeding or incarcerated individuals.\n* Non-English speaking\n* Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds",true,"ALL","18 Years","70 Years",{"count":74,"type":75},150,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.\n\nThe purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.\n\nThe investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.",[81,82,83,84],"Wounds","Wound of Skin","Wound Heal","Wounds and Injuries",[86,87],"4 aminopyridine","wound healing","2025-09-01",{"date":90,"type":91},"2025-09-03","ACTUAL",{"date":93,"type":75},"2025-09",{"date":95,"type":75},"2028-03",{"name":61,"class":6},1]